EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prospective Evaluation of Health-Related Quality of Life in Patients with Metastatic Urothelial Carcinoma Undergoing Immunotherapy with Pembrolizumab: Symptom Burden Can Predict Survival

Laila Schneidewind, Desirée Louise Dräger, Vanessa Roßberg, Julia Nolting, Oliver W Hakenberg

Urologia Internationalis · 2023 · 107 (1) · 80-86

DOI: 10.1159/000526962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Urologia Internationalis, online erschienen am 14.10.2022. Verfasst von Laila Schneidewind und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Medical Center Rostock, Rostock, Germany. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Despite the fact that guidelines recommend monitoring of quality of life during all phases of treatment in urothelial carcinoma, prospective data about health-related quality of life (HRQoL) in metastatic urothelial carcinoma undergoing immunotherapy are sparse. Consequently, we performed a prospective clinical pilot study about HRQoL using the Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator (FACT-ICM) questionnaire. Materials and Methods: Formally, this study is a prospective uni-centric noninterventional observation from January 2021 to December 2021.

Results

Fourteen patients with a mean age of 73.9 years (SD 8.8) participated in the study. The physical well-being subscale of FACT-G is most impaired during therapy with mean scores of 7.5, 6.2, and 4.0 followed by the emotional well-being. The FACT-G total score is stable during therapy with mean scores of 51.1, 50.4, and 48.0 and it is not significantly decreasing during therapy (p = 0.317). Furthermore, the symptom burden of these patients is low and not significantly changing over time (p = 0.500), but survival decreases significantly if symptom burden is high (FACT-ICM score over 40; p < 0.001).

Conclusion

Physical and emotional needs have a strong impact on HRQoL and should be dealt with during treatment. If symptom burden is high, survival decreases. This needs further evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellUrinary Bladder NeoplasmsHumansAgedQuality of LifePilot ProjectsImmunotherapyAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Functional assessment of cancer therapyHealth-related quality of lifeImmunotherapyMetastatic urothelial carcinomaPembrolizumab

Substanzen

pembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Urology, University Medical Center Rostock, Rostock, Germany.

Zitieren

APA

Schneidewind, L., Dräger, D. L., Roßberg, V., Nolting, J., & Hakenberg, O. W. (2023). Prospective Evaluation of Health-Related Quality of Life in Patients with Metastatic Urothelial Carcinoma Undergoing Immunotherapy with Pembrolizumab: Symptom Burden Can Predict Survival. Urologia Internationalis, 107(1), 80-86. https://doi.org/10.1159/000526962

Vancouver

Schneidewind L, Dräger DL, Roßberg V, Nolting J, Hakenberg OW. Prospective Evaluation of Health-Related Quality of Life in Patients with Metastatic Urothelial Carcinoma Undergoing Immunotherapy with Pembrolizumab: Symptom Burden Can Predict Survival. Urologia Internationalis. 2023;107(1):80-86. doi:10.1159/000526962

BibTeX
@article{Schneidewind2023,
  author = {Schneidewind, Laila and Dräger, Desirée Louise and Roßberg, Vanessa and Nolting, Julia and Hakenberg, Oliver W},
  title = {Prospective Evaluation of Health-Related Quality of Life in Patients with Metastatic Urothelial Carcinoma Undergoing Immunotherapy with Pembrolizumab: Symptom Burden Can Predict Survival},
  journal = {Urologia Internationalis},
  year = {2023},
  volume = {107},
  number = {1},
  pages = {80--86},
  doi = {10.1159/000526962}
}
Kostenlos starten →